By advising some of the fastest growing biotechs, we move as fast as our clients' needs - staying ahead of the trends. Whilst the financial markets are proving more receptive to biotechs than in the past few years, access to capital is still limited, emphasising the need for a strong business case and development pipeline. Consolidation is seen as one solution, however, there is also a noticeable increase in early stage licensing deals to secure much needed funding for the sector.

  • The syndicate of underwriting banks on Circassia’s IPO on the London Main Market in March 2014, London’s largest biotech flotation for decades.
  • Ascendis Pharma on its global licensing and patent transfer agreement with Sanofi Aventis concerning Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology.
  • Cryo-Save, Europe’s largest adult stem cell storage bank, on the secondary listing of its shares on Euronext Amsterdam by NYSE Euronext (alongside the company’s listing on AIM).
  • Genmab on various US and European collaboration and licensing arrangements concerning transgenic mice and fully human antibodies.